Alterations of Immunologic Mediators During Severe Sepsis (LAVISS_01)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00484146
(anticipated number of patients could not be reached)
Severe sepsis induces significant changes in expression of insulin- and toll-like receptors, cytokines, markers of apoptosis, and activation of t- and b-lymphocytes.
Condition or disease
In patients at early stage of severe sepsis, we investigate the expression of pro- and anti-inflammatory cytokines, chemokines, adhesion-molecules, toll-like receptors, insulin-receptors, markers of apoptosis und of t- and b-cell-activation on a mRNA level.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with early stage of severe sepsis and septic shock
age >= 18 y
agreement with study procedures
3 of 4 SIRS-criteria
proven or highly suspected infection
2 or more sepsis-induced organ failures
start of first sepsis-induced organ failure within the last 36 hours
non-agreement with study procedures
signs of severe sepsis with organ failure > 36 hours